Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Weight Management Clear all
Completed Not applicable Interventional

Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis , Full Scale Trial

NCT04194164
View directory record Official record
Conditions
Weight Gain
Interventions
Fluid intake app
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 25, 2026, 1:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men

NCT02362737
View directory record Official record
Conditions
Chronic Disease, Obesity, Hypertension, Diabetes, Self Care, Medication Adherence
Interventions
Active and Healthy Brotherhood (AHB)
Behavioral
Lead sponsor
Gramercy Research Group
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
aleniglipron or placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Glendale, California • Montclair, California • Valparaiso, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
49
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Collaborative Management in Pediatrics (CMP) Training Program Among Pediatric Resident Doctors and Their Patients With Asthma or Obesity

NCT00510341
View directory record Official record
Conditions
Education, Asthma, Obesity
Interventions
Collaborative Management in Pediatrics (CMP) Program
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
2 Years to 12 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

HealthyMe Online Weight Management Education/HealthyMe at Home

NCT02057952
View directory record Official record
Conditions
Diabetes
Interventions
Education and exercise
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

NCT07842640
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Lifestyle Management of CKD in Obese Diabetic Patients

NCT02276742
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions
Social Cognitive Theory, Monitoring
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults

NCT07221279
View directory record Official record
Conditions
Dyslipidemia, Insulin Resistance Syndrome, Hypertension, Inflammation Chronic, Obesity & Overweight
Interventions
Step counts for predictable changes in body weight/compositon and cardiometabolic risk
Behavioral
Lead sponsor
Kennesaw State University
Other
Eligibility
20 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
71
States / cities
Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06693843
View directory record Official record
Conditions
Obesity, Overweight, or Chronic Weight Management
Interventions
Aleniglipron or Placebo, Aleniglipron
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
39
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

NCT06679959
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC30 Injection, for subcutaneous use or placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654374
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Interventions
aleniglipron, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Health Promotion and Wellness Program for Adults With Disabling Conditions

NCT01776034
View directory record Official record
Conditions
Stroke, Multiple Sclerosis, Rheumatoid Arthritis
Interventions
SystemCHANGE Group Lifestyle counseling, Phone Lifestyle Counseling
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 25, 2026, 1:48 PM EDT
Not listed Not applicable Interventional

Simultaneously Targeting Obesity and Pain: The STOP Trial

NCT02100995
View directory record Official record
Conditions
Obesity, Chronic Pain
Interventions
Intervention Simultaneously Targeting Obesity and Pain, Weight Loss/Weight Self-Management, Chronic Pain Self-Management
Behavioral
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight

NCT07893093
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC36 Injection A, for subcutaneous use, ASC36 Placebo Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use, ASC36 Placebo Injection B, for subcutaneous use
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Bridging the Gap From Postpartum to Primary Care

NCT05543265
View directory record Official record
Conditions
Hypertension, Hypertension in Pregnancy, Diabetes Mellitus, Gestational Diabetes, Obesity, Depressive Disorder, Anxiety Disorders
Interventions
Default appointment scheduling, Targeted messaging, Nudge Reminders
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Food as Medicine: A Quasi-Randomized Control Trial of Healthy Foods for Chronic Disease Management

NCT05174078
View directory record Official record
Conditions
Obesity, Hypertension, Pre-diabetes, Type 2 Diabetes
Interventions
Medically-tailored meals, Produce box and recipes
Other
Lead sponsor
Cleveland Clinic Akron General
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

NCT00261833
View directory record Official record
Conditions
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Interventions
Alpha1-proteinase inhibitor, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

NCT06282458
View directory record Official record
Conditions
Muscle Loss, Obesity
Interventions
Enobosarm, Semaglutide
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
60 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
14
States / cities
Anniston, Alabama • Cullman, Alabama • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT07553299
View directory record Official record
Conditions
Obesity, Overweight, Weight Maintenance
Interventions
VRB-101, Placebo
Drug
Lead sponsor
Verdiva Bio Dev Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
20
States / cities
Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 1:48 PM EDT